This LTE study of subcutaneous tocilizumab in pJIA and sJIA adds to the body of evidence for long-term safety and efficacy of biologic therapy, particularly interleukin-6 inhibition, for disease control in JIA [25–28], with no new safety signals identified with long-term subcutaneous tocilizumab treatment. This evidence concerns the gene IL6 and juvenile idiopathic arthritis.